Health Care Equipment

MICROPORT EP

MICROPORT EP released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 125.93 M, actual EPS CNY 0.0618

MICROPORT EP FY2026 Q1 Earnings Release on April 30 After-Market BJT

MICROPORT EP to Release FY2025 Annual Earnings on March 31 Pre-Market (BJT), Forecast Revenue CNY 490.63 M, EPS CNY 0.1436

MICROPORT EP released FY2025 earnings on February 11 Pre-Market (BJT), actual revenue CNY 464.53 M (forecast CNY 490.63 M), actual EPS CNY 0.1087 (forecast CNY 0.1436)

MICROPORT EP released FY2025 Q4 earnings on February 11 Pre-Market (BJT), actual revenue CNY 128.13 M, actual EPS CNY 0.0194

MICROPORT EP released FY2025 Q3 earnings on October 27 During-Market (BJT), actual revenue CNY 112.65 M, actual EPS CNY 0.0196

MICROPORT EP released FY2025 9 Months Earnings on October 27 During-Market (BJT), Actual Revenue CNY 336.4 M, Actual EPS CNY 0.089

MICROPORT EP to Release FY2025 Q3 Earnings on October 28 During-Market BJT

MICROPORT EP released FY2025 Semi-Annual earnings on August 26 After-Market (BJT), actual revenue CNY 223.75 M, actual EPS CNY 0.0694

MICROPORT EP released FY2025 Q2 earnings on August 26 After-Market (BJT), actual revenue CNY 119.65 M, actual EPS CNY 0.0314

MICROPORT EP to release FY2025 Semi-Annual earnings report on August 27, 2025 (BJT)

Analysts at China Post Securities Release Research Report on Micro-Pacesetter

Microelectrophysiology Sees Steady Q1 Revenue Growth

Microelectrophysiology Shares Surge, Receive Multiple 'Buy' Ratings

Microelectrophysiology's Q1 2025 Net Profit Up 328.63%

MICROPORT EP released FY2025 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 104.1 M (forecast CNY 104 M), actual EPS CNY 0.038

MICROPORT EP FY2025 Q1 Earnings Release on April 30 After-Market BJT

MICROPORT EP to Release FY2024 Earnings on March 28 After-Market BJT, Forecast Revenue 438.3 M CNY, EPS 0.0859 CNY

MICROPORT EP released FY2024 earnings on February 24 After-Market (BJT), actual revenue CNY 413.17 M (forecast CNY 438.3 M), actual EPS CNY 0.1106 (forecast CNY 0.0859)

MICROPORT EP released FY2024 Q4 earnings on February 24 After-Market (BJT), actual revenue CNY 122.3 M, actual EPS CNY 0.0219

02160

688351

00853

02172

02252

159883

562600

159898

688016

Bank of America Securities has lowered the target price for MICROPORT to 13.9 yuan, reiterating a "Buy" rating. It expects total revenue in 2025 to be USD 1.105 billion, with a year-on-year increase of 6% after excluding foreign exchange factors. Its "GloMatrix" platform has achieved breakeven, and revenue for the fiscal year 2025 is expected to grow by 78.8% to 163.9 million yuan. Due to the exclusion of MICROPORT NEURO from the consolidated financial statements, revenue forecasts for 2026 to 2028 have been reduced by 10.9% to 12.9%. At the same time, gross margin forecasts have been raised by 1.9 to 2.1 percentage points, and operating expense ratio forecasts have been raised by 11.5 to 12.6 percentage points

AASTOCKS

MP CARDIOFLOW-B

MICROPORT

MICROPORT NEURO

MircroPort Medbot-B

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Endovastec

Bank of America Securities lowers the target price for MicroPort to 13.9 yuan, reiterating a "Buy" rating

Shares of MicroPort Endovascular MedTech Group surged 10.2% to CNY111.80 after the US FDA granted Breakthrough Device Designation to its innovative stent graft system, expediting market approval. The Hector Multi-Branch Thoracic Aortic Stent Graft System aims for minimally invasive treatment of thoracic aortic lesions. MicroPort reported a 12% rise in net profit to CNY563 million last year, driven by innovative product launches and a 55% increase in overseas sales. The device has received EU certification and is in clinical trials in China, addressing high-risk aortic arch lesions with less invasive methods.

Yicai

China's MicroPort Soars After US Grants Its New Stent Breakthrough Device Status

Microelectrophysiology announced that its magnetic navigation ablation catheter and star-shaped high-density mapping catheter have recently received certification under the European Union Medical Device Regulations (EU) 2017/745. According to Jin10, this certification marks a significant milestone for the company, allowing it to expand its market presence in the European medical device sector. The certification ensures that the products meet the stringent safety and performance standards required by the EU, potentially enhancing their competitiveness in the global market.

CoinLive

Microelectrophysiology's Catheters Receive EU MDR Certification

MICROPORT opened high today at 6.34%, reaching a maximum of 13.95 yuan. It is currently reported at 13.45 yuan, up 7.95%, with a trading volume of 15.7865 million shares, involving a capital of 213 million yuan. The company recently issued a profit warning, expecting to turn a profit in the fiscal year 2025, with a net profit of no less than 20 million USD, compared to a net loss of 268 million USD in the previous year

MicroPort rose nearly 8% after issuing a profit warning, expecting to turn a profit last year

On the evening of August 26, MICROPORT EP disclosed its semi-annual report for 2025, achieving operating revenue of 224 million yuan in the first half of the year, a year-on-year increase of 12.8%; net profit attributable to the parent company was 32.6681 million yuan, a year-on-year increase of 92.02%; basic earnings per share were 0.0694 yuan. The changes in operating data were mainly due to the growth in sales scale during the reporting period and the profit growth brought about by cost reduction and efficiency improvement

Zhitong

MICROPORT EP: Net profit in the first half of the year was 32.6681 million yuan, a year-on-year increase of 92.02%

MICROPORT EP expects the net profit attributable to the parent company for the first half of 2025 to be between 30 million and 35 million yuan, an increase of 76.34% to 105.73% year-on-year. The company focuses on the field of cardiac electrophysiology and actively expands the atrial fibrillation treatment market, relying on multiple technological advantages. Thanks to the successful promotion of new products overseas, the company's overseas market sales performance has been outstanding, driving significant growth in overall sales and net profit

MICROPORT EP expects a half-year net profit attributable to the parent company of 30 million to 35 million yuan, an increase of 76.34% to 105.73% year-on-year

MICROPORT EP announced that its IceMagic® balloon cryoablation catheter has obtained EU Medical Device Regulation (MDR) certification. This marks the official entry of the company's cryo series products into the international market, helping to enhance brand awareness and expand overseas markets

MICROPORT EP: IceMagic ® balloon-type cryoablation catheter has obtained EU MDR certification

MICROPORT EP(688351.SH)